[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371720-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371720-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","unraveling-the-glyco-immunity-nexus-in-pancreatic-cancer-review","Unraveling the glyco-immunity nexus in pancreatic cancer - Review","","Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease in which standard therapies have provided limited clinical benefit, leaving invasive surgery as the only curative option for early-stage patients. Tumor-associated glycans directly support tumor survival and propagation while shaping an immunosuppressed tumor microenvironment. The review explains a PDAC “tumor glycocode” and emphasizes hypersialylation as central features. It describes glycan-binding proteins including C-type lectin receptors, Siglecs, and Galectins, links glycan regulation to impaired anti-tumor immunity via MHC and immune checkpoints like PD-L1 and CTLA-4, and summarizes glycan-targeted therapies and emerging single-cell approaches.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/unraveling-the-glyco-immunity-nexus-in-pancreatic-cancer-review/371720/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/unraveling-the-glyco-immunity-nexus-in-pancreatic-cancer-review/371720.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-22","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is PDAC difficult to treat with standard therapies?","Question",{"text":63,"@type":64},"PDAC is extremely aggressive, and current standard-of-care therapies have not produced significant clinical benefit, with invasive surgery remaining the only curative option for early-stage disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do tumor-associated glycans influence the immune environment?",{"text":68,"@type":64},"Tumor-associated glycans directly affect tumor survival and propagation and contribute to an immunosuppressed tumor microenvironment that dampens anti-tumor immunity.",{"name":70,"@type":61,"acceptedAnswer":71},"Which molecular interactions and checkpoints are highlighted in glyco-immune regulation?",{"text":72,"@type":64},"The review discusses glycan-binding proteins such as C-type lectin receptors, Siglecs, and Galectins, and explains how glycan-mediated regulation impacts MHC and increases immune checkpoint expression including PD-L1 and CTLA-4.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371720,1791093904,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Rajesh et al. Molecular Cancer (2025) 24:211 [https://doi.org/10.1186/s12943-025-02417-4](https://doi.org/10.1186/s12943-025-02417-4)  \nMolecular Cancer  \nREVIEW Open Access  \nUnraveling the glyco-immunity nexus in pancreatic cancer  \nChristabelle Rajesh 1, Richard D. Cummings2 and Prakash Radhakrishnan 1,3,4*  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive disease, and standard of care therapies have failed to yield significant clinical benefit, with invasive surgery being the only curative treatment for patients with early-stage disease. Tumor-associated glycans in pancreatic cancer have direct effects on the survival and propagation of the tumor proper and contribute to an immunosuppressed tumor microenvironment. The existence of a “tumor glycocode” in PDAC and the role of hypersialylation in this cancer have been hugely underscored. Through this initial understanding, significant strides have been made in the field of glycosylation-mediated immune regulation, uncovering glyco-immune checkpoints that facilitate tumor progression in PDAC and other malignancies. Here, we describe the specific roles of glycan-binding proteins, such as C-type lectin receptors, Siglecs, and Galectins, in generating and promoting immunosuppression, exacerbating survival outcomes, and dampening therapeutic efficacy. We illustrate the scale of glycan-mediated regulation of homeostatic immune responses and how cancer glycans facilitate dampened anti-tumor immunity through the major histocompatibility complex (MHC) and the enhanced expression of immune checkpoints, such as PD-L1 and CTLA-4 . A wide array of glycan-targeted therapies against PDAC in the clinic, including monoclonal antibodies, enzymes, and vaccines, has been described. With the help of new glycosylation signatures identified and techniques that allow us to reach single-cell resolution, we can target glycans and generate strategies to activate the immune system against PDAC. Keywords Pancreatic cancer, Tumor glycosylation, Tumor microenvironment, Immune signaling, Therapies  \n*Correspondence:  \nPrakash Radhakrishnan  \n[prakash.radhakrishnan@louisville.edu](prakash.radhakrishnan@louisville.edu)  \n1Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA  \n2Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA  \n3Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA  \n4UofL Health-Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA  \nIntroduction  \nPost-translational modifications (PTMs) of proteins can have a profound structural impact, leading to entirely new consequences for their function. At the dawn of the 20th century, P.A. Levene and C.L. Alsberg reported the first phosphorylation of a protein, vitillin (vitillinic acid), at a serine residue using innovative analytical chemistry in 1906 [1]. Over a century later, more than 500 PTMs have been identified and studied for their biological functions [2–15]. All these PTMs confer unique properties toa protein via covalent modification, which can encompass the addition of a functional group or proteolytic cleavage, allowing for varied protein functionality that regulates intricate processes such as protein-protein interactions, cellular localization, and more at the molecular level [16].  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this articl","cbCaivCniz5eP0sD","https://ap.wps.com/l/cbCaivCniz5eP0sD","pdf",2722449,26,"English","# Abstract\n# Introduction","[{\"question\":\"Why is PDAC difficult to treat with standard therapies?\",\"answer\":\"PDAC is extremely aggressive, and current standard-of-care therapies have not produced significant clinical benefit, with invasive surgery remaining the only curative option for early-stage disease.\"},{\"question\":\"How do tumor-associated glycans influence the immune environment?\",\"answer\":\"Tumor-associated glycans directly affect tumor survival and propagation and contribute to an immunosuppressed tumor microenvironment that dampens anti-tumor immunity.\"},{\"question\":\"Which molecular interactions and checkpoints are highlighted in glyco-immune regulation?\",\"answer\":\"The review discusses glycan-binding proteins such as C-type lectin receptors, Siglecs, and Galectins, and explains how glycan-mediated regulation impacts MHC and increases immune checkpoint expression including PD-L1 and CTLA-4.\"}]","Unraveling the glyco-immunity nexus in pancreatic cancer - Review | PDF",1790192699,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/133b7ffbef7f28d84a65a8af6f95f1d4.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/574660f5f371fb7bd9defa2d8ed7d9d0.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c375c9e05f5fc4914e05e1e73a2eeb0d.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29cb165197f76cc831a7adf8c578ac24.webp",980,1306]